Heart drug cuts death and heart attack rate by 40 percent in angioplasty-stent procedure

March 13, 2000

ANAHEIM, Calif. -- A drug designed to prevent blood clots from developing during a common heart procedure performed so well that the Duke University physicians who tested it predict it will alter medical practice.

The drug eptifibatide (tradename Integrilin) cut deaths and heart attacks by 40 percent in the first 48 hours after it was used in patients who received a balloon angioplasty, which uses a catheter to press artery-obstructing plaque flat, and the implant of a stent, a mesh-like device that props the artery open. Eptifibatide's benefit was consistent in all groups of patients studied in the trial.

The finding is important for patients because eptifibatide is a much more affordable alternative than the only other agent in the class of drugs that has been shown to be effective in preventing clots during the procedure. That drug, abciximab (tradename Reopro), costs $1,500, compared to $400 for eptifibatide.

"Now only about 20 percent of patients being treated with a coronary stent receive platelet inhibitor therapy," said the study's principal investigator, Dr. James Tcheng, a cardiologist at the Duke Clinical Research Institute. "The main reason more patients are not being treated with these drugs is the high cost of treatment.

"Eptifibatide is a more affordable drug which we have now shown to be highly effective in coronary stenting," Tcheng said in an interview. "This could make a dramatic difference in the outcomes of patients treated with a stent angioplasty procedure."

Tcheng prepared the results of the trial, known as ESPRIT (Enhanced Suppression of the Platelet Receptor glycoprotein IIb/IIIa using Integrilin Therapy), for presentation Tuesday at the annual scientific meeting of the American College of Cardiology. ESPRIT was funded COR Therapeutics Inc., and Schering-Plough Corp., developers of eptifibatide.

The trial was halted ahead of schedule in February because an interim analysis showed highly significant reductions in the rates of death or heart attack at both 48 hours and at 30 days. An Independent Data and Safety Monitoring Committee thought it would be unethical to continue to offer only half of patients treatment with eptifibatide when the drug had proved effective.

Nearly 600,000 coronary angioplasty procedures are performed in the United States each year to restore blood flow through blocked arteries, and more than 80 percent of these procedures use stents. But the procedure carries risks - deploying a catheter and stent can disrupt the wall of an artery, and can promote the clumping together of blood platelet cells to form blood clots.

Eptifibatide was given intravenously to patients in the trial immediately before and during an angioplasty, as well as for an average of 18 hours following the procedure. The drug is classified as a "small molecule" inhibitor and works by blocking the key glycoprotein IIb/IIIa receptor on platelets that are responsible for the formation of blood clots. The drug is one of two small molecule inhibitors on the market approved to treat acute coronary syndromes. Of these two, however, only eptifibatide has been tested in stent procedures. Abciximab -- also a platelet inhibitor, but formulated in a different was, as a monoclonal antibody IIb/IIIa platelet inhibitor -- has also been found to be effective in stenting procedures.

ESPRIT was a double-blind, randomized, placebo-controlled trial that enrolled 2,064 patients at 92 hospitals in the United States and Canada. The primary endpoint of the study was at 48 hours; the combined incidence of death, heart attack, urgent repeat angioplasty or coronary artery bypass surgery; or the need for an emergency "bail-out" platelet inhibitor therapy. Researchers found: There was an increased risk of minor and major bleeding with eptifibatide treatment. The majority of excess bleeding occurred at the point of access into the femoral artery for the angioplasty procedure, Tcheng noted.
-end-


Duke University Medical Center

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.